Search

Displaying results 1991 - 2000 of 10000 in total
  1. Drug

    Trospium

    go.drugbank.com/drugs/DB00209
    ApprovedInvestigational

    [L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211] … Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably.

  2. Drug

    Nabumetone

    go.drugbank.com/drugs/DB00461
    Approved

    [label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. … [label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen].

    Mixtures: NuDroxiPAK N-500
  3. Drug

    Fostemsavir

    go.drugbank.com/drugs/DB11796
    ApprovedInvestigational

    [A215057] Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant … prevents the first step in the HIV-1 viral lifecycle.

  4. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. … [L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838]

  5. Drug

    Margetuximab

    go.drugbank.com/drugs/DB14967
    ApprovedInvestigational

    produced in Chinese Hamster Ovary (CHO) culture. … [A225751] The introduction of [trastuzumab] improved patient outcomes in HER2-positive breast cancer, but notably depended substantially on polymorphisms in the FcγRIIIA/CD16A receptor, whereby low affinity

  6. Drug

    Ripasudil

    go.drugbank.com/drugs/DB13165
    Investigational

    It was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. … Ripasudil is a well tolerated medication that is used when other drugs have been proven to be non-effective or cannot be administered.

    Categories: Sympathomimetics in Glaucoma Therapy
  7. Drug

    Latamoxef

    go.drugbank.com/drugs/DB04570
    Approved

    Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins … It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.

  8. Drug

    Allopurinol

    go.drugbank.com/drugs/DB00437
    ApprovedInvestigational

    It was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [L5677]. … This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals [A175942].

  9. Drug

    Sulfacetamide

    go.drugbank.com/drugs/DB00634
    Approved

    An anti-infective agent that is used topically to treat skin infections and orally for urinary tract infections.

    Mixtures: Sodium Sulfacetamide and Sulfur Clarifying Wash in a Urea VehicleSynonyms: N-Acetylsulfanilamide, N-Sulfanilylacetamide
  10. Drug

    Ceritinib

    go.drugbank.com/drugs/DB09063
    ApprovedInvestigational

    The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status. … Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the enzyme.

    Synonyms: N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide